CO2020009992A2 - Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación - Google Patents

Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación

Info

Publication number
CO2020009992A2
CO2020009992A2 CONC2020/0009992A CO2020009992A CO2020009992A2 CO 2020009992 A2 CO2020009992 A2 CO 2020009992A2 CO 2020009992 A CO2020009992 A CO 2020009992A CO 2020009992 A2 CO2020009992 A2 CO 2020009992A2
Authority
CO
Colombia
Prior art keywords
bilastine
cyclodextrin
gelling agent
beta
ophthalmic compositions
Prior art date
Application number
CONC2020/0009992A
Other languages
English (en)
Inventor
Herrero Gonzalo Hernández
Poladura Pablo Morán
Gorostiza Ana Gonzalo
Cerdeiras Paloma Tato
Arce Arturo Zazpe
Hernando Nieves Fernández
García Tania González
Espinar Francisco Javier Otero
Ferreiro Anxo Fernández
Tomé Victoria Díaz
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of CO2020009992A2 publication Critical patent/CO2020009992A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una composición farmacéutica oftálmica acuosa que comprende: a) al menos el 0,4% p/v de bilastina, de fórmula o una sal o solvato farmacéuticamente aceptable de la misma, en la que la bilastina, sal o solvato de la misma se disuelve completamente en la composición farmacéutica; b) al menos una -ciclodextrina; y c) al menos un agente de gelificación soluble en agua farmacéuticamente aceptable; y en la que el pH está comprendido entre 4 y 9, y a su uso en el tratamiento y/o la prevención de estados mediados por receptor de histamina H1, tales como trastornos o enfermedades alérgicos. La invención se refiere al tratamiento y/o prevención de conjuntivitis alérgica.
CONC2020/0009992A 2018-01-18 2020-08-13 Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación CO2020009992A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382021 2018-01-18
PCT/EP2019/050433 WO2019141563A1 (en) 2018-01-18 2019-01-09 Ophthalmic compositions comprising bilastine, a beta-cyclodextrin and at least one gelling agent

Publications (1)

Publication Number Publication Date
CO2020009992A2 true CO2020009992A2 (es) 2021-01-18

Family

ID=61017875

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0009992A CO2020009992A2 (es) 2018-01-18 2020-08-13 Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación

Country Status (25)

Country Link
US (1) US20210128544A1 (es)
EP (2) EP3740191B1 (es)
JP (1) JP7309729B2 (es)
KR (1) KR20200111727A (es)
AR (1) AR114216A1 (es)
AU (1) AU2019209214B2 (es)
BR (1) BR112020014265A2 (es)
CA (1) CA3088740A1 (es)
CL (1) CL2020001895A1 (es)
CO (1) CO2020009992A2 (es)
CY (1) CY1124270T1 (es)
DK (1) DK3740191T3 (es)
EA (1) EA202091725A1 (es)
ES (1) ES2878107T3 (es)
HR (1) HRP20211037T1 (es)
HU (1) HUE054594T2 (es)
LT (1) LT3740191T (es)
MA (1) MA51612B1 (es)
MX (1) MX2020007692A (es)
PL (1) PL3740191T3 (es)
PT (1) PT3740191T (es)
SA (1) SA520412443B1 (es)
SI (1) SI3740191T1 (es)
UY (1) UY38055A (es)
WO (1) WO2019141563A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023156559A1 (en) 2022-02-17 2023-08-24 Faes Farma, S.A. Bilastine composition for once-daily parenteral administration

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
ES2048109B1 (es) 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
JP3527256B2 (ja) 1992-12-09 2004-05-17 ロート製薬株式会社 抗アレルギー点眼剤
TW401300B (en) * 1992-12-25 2000-08-11 Senju Pharma Co Antiallergic composition for ophthalmic or nasal use
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
DE10161149B4 (de) 2001-12-12 2007-03-08 Ursapharm Arzneimittel Gmbh & Co. Kg Verwendung von Heparin-haltigem Ophthalmikum
BRPI0215703B8 (pt) 2002-04-19 2021-05-25 Faes Farma Sa polimorfo de ácido 4-[2-[1-(2-etoxietil)-1h-benzidimazol-2-il]-1-piperidinil]etil]-a, a-dimetil-benzenoacético, preparado farmacêutico, e seu uso do polimorfo 1
US20050239745A1 (en) * 2004-03-03 2005-10-27 Ophthalmic Research Associates, Inc. Novel topical ophthalmic formulations
US7247623B2 (en) 2005-08-19 2007-07-24 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with non-drying antihistamines
WO2007047253A2 (en) 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
MX2008012657A (es) * 2006-03-31 2009-02-19 Vistakon Pharmaceuticals Llc Tratamientos de las alergias oculares.
CN106038481A (zh) 2007-06-28 2016-10-26 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
WO2010107525A1 (en) 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
CN103110575B (zh) * 2013-03-07 2014-11-05 宁夏康亚药业有限公司 一种美洛昔康滴眼液及其制备方法和应用
WO2014150899A1 (en) 2013-03-15 2014-09-25 Chapin Matthew J Topical ophthalmic formulations for treating migraine
CN103784462A (zh) 2014-02-25 2014-05-14 宋俊智 包含比拉斯汀及甾族化合物的药物制剂
EP3040334A1 (en) 2014-12-29 2016-07-06 Faes Farma, S.A. New benzimidazole derivatives as antihistamine agents

Also Published As

Publication number Publication date
WO2019141563A1 (en) 2019-07-25
MA51612B1 (fr) 2021-06-30
BR112020014265A2 (pt) 2020-12-08
JP7309729B2 (ja) 2023-07-18
EP3740191B1 (en) 2021-04-28
MA51612A (fr) 2020-11-25
CA3088740A1 (en) 2019-07-25
HRP20211037T1 (hr) 2021-10-01
EA202091725A1 (ru) 2020-10-12
AU2019209214B2 (en) 2023-11-23
PT3740191T (pt) 2021-07-09
AR114216A1 (es) 2020-08-05
TW201932110A (zh) 2019-08-16
KR20200111727A (ko) 2020-09-29
LT3740191T (lt) 2021-08-10
CY1124270T1 (el) 2022-07-22
CL2020001895A1 (es) 2020-12-04
EP3740191A1 (en) 2020-11-25
JP2021511317A (ja) 2021-05-06
SI3740191T1 (sl) 2021-09-30
MX2020007692A (es) 2020-09-14
DK3740191T3 (da) 2021-06-07
UY38055A (es) 2019-08-30
PL3740191T3 (pl) 2021-11-29
AU2019209214A1 (en) 2020-08-13
CN111727035A (zh) 2020-09-29
HUE054594T2 (hu) 2021-09-28
EP3915539A1 (en) 2021-12-01
SA520412443B1 (ar) 2022-09-01
ES2878107T3 (es) 2021-11-18
US20210128544A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
PE20191650A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
EA200700109A1 (ru) Способы лечения офтальмологических состояний (варианты)
NO20063693L (no) Forbindelse og metode for anvendelse
BR112022003514A2 (pt) Degradadores bifuncionais de brd9 e seus métodos de uso
BR112019000849A2 (pt) composições líquidas de limpeza com sistema antibacteriano e método de fabricação das mesmas
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
MA32764B1 (fr) Inhibiteurs de l'intégrase du vih
MA40886B1 (fr) Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih
JP2018532806A5 (es)
EA202190153A1 (ru) Составы ингибитора axl/mer
EA201992090A1 (ru) ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
CO2020009992A2 (es) Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación
MX2021013135A (es) Derivados de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2.
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2020010552A (es) Derivados de bumetanida para el tratamiento de la hiperhidrosis.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
CL2020001156A1 (es) Formulaciones de liberación prolongada para aplicaciones intra-articulares.
AU2017261303A1 (en) Ophthalmic compositions
MX2021003901A (es) Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
CO2020005939A2 (es) Composiciones acuosas que comprenden bilastina y mometasona
PE20211978A1 (es) Compuesto heterociclo pentaciclico
MX2020001356A (es) Composiciones farmaceuticas.
PE20091836A1 (es) Formulaciones para el oido para tratar enfermedades y condiciones oticas